Roche and Affymetrix get US nod for first-of-its-kind DNA test
This article was originally published in Clinica
Executive Summary
The US FDA has cleared, for the first time, a DNA microarray test that could help doctors determine the success of medications for a variety of conditions, including cardiac disease, psychiatric disease and cancer. The AmpliChip Cytochrome P450 genotyping test, made by Roche Molecular Systems, of Pleasanton, California was cleared for use with Affymetrix' GeneChip Microarray system. According to the agency, the product could pave the way for the development of similar tests.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.